Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
drugs
alnylam pharmaceuticals
boston blog main
life sciences
national blog main
boston
boston top stories
clinical trials
rna interference
aminolevulinic acid
fda
givosiran
new york blog main
new york top stories
onpattro
patisiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
biotech
cells
european medicines agency
evercore isi
evolocumab
extreme
harvard pilgrim health care
heart attack
hereditary transthyretin amyloidosis
inclisiran
inotersen
institute for clinical and economic review
joseph swartz
medicine
medicines co.
national top stories
new york
What
drug
6
×
rna
6
×
alnylam
interference
medicine
new
pharmaceuticals
rnai
based
data
fda
second
seek
speedy
abandoned
adapting
ago
approval
approves
away
big
cells
cholesterol
class
cleared
cofactor
company
consumer
dangerous
diagnostics
discovery
effective
ema
employ
europe
evidence
far
follows
gene
genomics
Language
Current search:
rna
×
drug
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@extremetech.com
8 years ago
Scientists find abandoned drug effective against two human viruses
@WIRED
8 years ago
Cofactor is an RNA sequencing company that's turning away from drug discovery for big pharma toward consumer diagnostics.